Logo image of PCIB.OL

PCI BIOTECH HOLDING ASA (PCIB.OL) Stock Fundamental Analysis

OSL:PCIB - Euronext Oslo - NO0010405640 - Common Stock - Currency: NOK

1.5  +0.24 (+19.05%)

Fundamental Rating

3

PCIB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. PCIB has a great financial health rating, but its profitability evaluates not so good. PCIB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PCIB had negative earnings in the past year.
PCIB had a negative operating cash flow in the past year.
In the past 5 years PCIB always reported negative net income.
In the past 5 years PCIB always reported negative operating cash flow.
PCIB.OL Yearly Net Income VS EBIT VS OCF VS FCFPCIB.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of PCIB (-52.59%) is comparable to the rest of the industry.
The Return On Equity of PCIB (-70.00%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.59%
ROE -70%
ROIC N/A
ROA(3y)-61.83%
ROA(5y)-57.01%
ROE(3y)-72.67%
ROE(5y)-66.77%
ROIC(3y)N/A
ROIC(5y)N/A
PCIB.OL Yearly ROA, ROE, ROICPCIB.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCIB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCIB.OL Yearly Profit, Operating, Gross MarginsPCIB.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

8

2. Health

2.1 Basic Checks

PCIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PCIB remains at a similar level compared to 1 year ago.
PCIB has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCIB has a worse debt to assets ratio.
PCIB.OL Yearly Shares OutstandingPCIB.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PCIB.OL Yearly Total Debt VS Total AssetsPCIB.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PCIB has an Altman-Z score of 3.96. This indicates that PCIB is financially healthy and has little risk of bankruptcy at the moment.
PCIB has a Altman-Z score of 3.96. This is amongst the best in the industry. PCIB outperforms 88.73% of its industry peers.
There is no outstanding debt for PCIB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.96
ROIC/WACCN/A
WACC8.63%
PCIB.OL Yearly LT Debt VS Equity VS FCFPCIB.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

PCIB has a Current Ratio of 3.98. This indicates that PCIB is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.98, PCIB is doing good in the industry, outperforming 78.87% of the companies in the same industry.
A Quick Ratio of 3.98 indicates that PCIB has no problem at all paying its short term obligations.
PCIB has a Quick ratio of 3.98. This is amongst the best in the industry. PCIB outperforms 80.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.98
Quick Ratio 3.98
PCIB.OL Yearly Current Assets VS Current LiabilitesPCIB.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

PCIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.20%, which is quite good.
PCIB shows a strong growth in Revenue. In the last year, the Revenue has grown by 125.25%.
Measured over the past years, PCIB shows a decrease in Revenue. The Revenue has been decreasing by -6.43% on average per year.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.63%
Revenue 1Y (TTM)125.25%
Revenue growth 3Y2.4%
Revenue growth 5Y-6.43%
Sales Q2Q%10.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCIB.OL Yearly Revenue VS EstimatesPCIB.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PCIB.OL Yearly EPS VS EstimatesPCIB.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCIB.OL Price Earnings VS Forward Price EarningsPCIB.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCIB.OL Per share dataPCIB.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCIB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PCI BIOTECH HOLDING ASA

OSL:PCIB (4/25/2025, 7:00:00 PM)

1.5

+0.24 (+19.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13
Earnings (Next)N/A N/A
Inst Owners3.92%
Inst Owner ChangeN/A
Ins Owners5.86%
Ins Owner ChangeN/A
Market Cap55.99M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.31
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.18
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.59%
ROE -70%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.83%
ROA(5y)-57.01%
ROE(3y)-72.67%
ROE(5y)-66.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.98
Quick Ratio 3.98
Altman-Z 3.96
F-Score4
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)125.25%
Revenue growth 3Y2.4%
Revenue growth 5Y-6.43%
Sales Q2Q%10.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.1%
OCF growth 3YN/A
OCF growth 5YN/A